A potential alternative to immunohistochemistry for predicting patients’ response to anti-PD-L1 therapy is to use testing based on the droplet digital polymerase chain reaction technique to detect changes in the mRNA expression levels in patients’ blood.
Read More
Circulating tumor DNA is a reliable biomarker of tumor progression following immunotherapy treatment.
Read MoreA blood-based proteomic test reliably assesses individual patient prognosis to inform treatment decisions and reduce costs associated with overtreatment in lung cancer.
Read More
The highly multiplexed ddPCR-based assay is currently in use by biopharma partners.
Read MoreProscia and Proteocyte AI have signed an agreement to integrate Proscia’s technology with the Straticyte test for predicting the risk of progression to oral cancer.
Read More